Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Approvals: J&J's Darzalex Steps Ahead With New Indication

Keytruda Cleared For First-Line Head & Neck Cancer

Executive Summary

The European Commission has approved Johnson & Johnson’s/Genmab’s CD38-targeted MAb, daratumumab, and Merck & Co’s checkpoint inhibitor, pembrolizumab, in two first-line additional indications, in multiple myeloma and head and neck cancer, respectively.

 

 

You may also be interested in...



GSK Gears Up For Three Cancer Launches In 2020

After selling off its oncology franchise just five years ago, GSK is poised to re-enter the fray - and is preparing its commercial teams for battle.

'Intriguing' data On GSK's ICOS Agonist For Head And Neck Cancer

As it continues to build a presence in oncology, the company is starting a late-stage trial of GSK3359609 combined with Merck & Co's blockbuster Keytruda on the back of data presented at ESMO.

Pipeline Watch: Roxadustat, Lascufloxacin Approvals In Japan

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141221

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel